PMID- 24018562 OWN - NLM STAT- MEDLINE DCOM- 20131126 LR - 20230708 IS - 1558-8238 (Electronic) IS - 0021-9738 (Print) IS - 0021-9738 (Linking) VI - 123 IP - 10 DP - 2013 Oct TI - Lipotoxicity disrupts incretin-regulated human beta cell connectivity. PG - 4182-94 LID - 68459 [pii] LID - 10.1172/JCI68459 [doi] AB - Pancreatic beta cell dysfunction is pathognomonic of type 2 diabetes mellitus (T2DM) and is driven by environmental and genetic factors. beta cell responses to glucose and to incretins such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are altered in the disease state. While rodent beta cells act as a coordinated syncytium to drive insulin release, this property is unexplored in human islets. In situ imaging approaches were therefore used to monitor in real time the islet dynamics underlying hormone release. We found that GLP-1 and GIP recruit a highly coordinated subnetwork of beta cells that are targeted by lipotoxicity to suppress insulin secretion. Donor BMI was negatively correlated with subpopulation responses to GLP-1, suggesting that this action of incretin contributes to functional beta cell mass in vivo. Conversely, exposure of mice to a high-fat diet unveiled a role for incretin in maintaining coordinated islet activity, supporting the existence of species-specific strategies to maintain normoglycemia. These findings demonstrate that beta cell connectedness is an inherent property of human islets that is likely to influence incretin-potentiated insulin secretion and may be perturbed by diabetogenic insults to disrupt glucose homeostasis in humans. FAU - Hodson, David J AU - Hodson DJ FAU - Mitchell, Ryan K AU - Mitchell RK FAU - Bellomo, Elisa A AU - Bellomo EA FAU - Sun, Gao AU - Sun G FAU - Vinet, Laurent AU - Vinet L FAU - Meda, Paolo AU - Meda P FAU - Li, Daliang AU - Li D FAU - Li, Wen-Hong AU - Li WH FAU - Bugliani, Marco AU - Bugliani M FAU - Marchetti, Piero AU - Marchetti P FAU - Bosco, Domenico AU - Bosco D FAU - Piemonti, Lorenzo AU - Piemonti L FAU - Johnson, Paul AU - Johnson P FAU - Hughes, Stephen J AU - Hughes SJ FAU - Rutter, Guy A AU - Rutter GA LA - eng GR - 12/0004431/DUK_/Diabetes UK/United Kingdom GR - 11/0004210/DUK_/Diabetes UK/United Kingdom GR - MR/J0003042/1/MRC_/Medical Research Council/United Kingdom GR - R01 GM077593/GM/NIGMS NIH HHS/United States GR - WT_/Wellcome Trust/United Kingdom GR - R01-GM077593/GM/NIGMS NIH HHS/United States GR - 098424/WT_/Wellcome Trust/United Kingdom GR - WT098424AIA/WT_/Wellcome Trust/United Kingdom PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20130909 PL - United States TA - J Clin Invest JT - The Journal of clinical investigation JID - 7802877 RN - 0 (Blood Glucose) RN - 0 (Fatty Acids, Nonesterified) RN - 0 (Incretins) RN - 0 (Insulin) RN - 89750-14-1 (Glucagon-Like Peptide 1) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Animals MH - Blood Glucose MH - Body Mass Index MH - Calcium Signaling MH - Cell Communication MH - Cells, Cultured MH - Diabetes Mellitus, Type 2/metabolism MH - Diet, High-Fat MH - Fatty Acids, Nonesterified/metabolism/pharmacology MH - Gap Junctions/metabolism MH - Glucagon-Like Peptide 1/physiology MH - Glucose/physiology MH - Homeostasis MH - Humans MH - Incretins/*physiology MH - Insulin/metabolism MH - Insulin Secretion MH - Insulin-Secreting Cells/*metabolism MH - Mice MH - Mice, Inbred C57BL MH - Species Specificity PMC - PMC4382273 EDAT- 2013/09/11 06:00 MHDA- 2013/12/16 06:00 PMCR- 2013/09/09 CRDT- 2013/09/11 06:00 PHST- 2012/12/21 00:00 [received] PHST- 2013/07/11 00:00 [accepted] PHST- 2013/09/11 06:00 [entrez] PHST- 2013/09/11 06:00 [pubmed] PHST- 2013/12/16 06:00 [medline] PHST- 2013/09/09 00:00 [pmc-release] AID - 68459 [pii] AID - 10.1172/JCI68459 [doi] PST - ppublish SO - J Clin Invest. 2013 Oct;123(10):4182-94. doi: 10.1172/JCI68459. Epub 2013 Sep 9.